Downregulation of SUMO2 inhibits hepatocellular carcinoma cell proliferation, migration and invasion

被引:9
作者
Chen, Jintu [1 ]
Chen, Canwei [2 ]
Lin, Yongfa [3 ]
Su, Yongfa [1 ]
Yu, Xueping [1 ]
Jiang, Yancheng [1 ]
Chen, Zixuan [1 ]
Ke, ShaoYing [1 ]
Lin, ShaoZe [1 ]
Chen, LiangJuan [1 ]
Zhang, Zhishan [1 ]
Zhang, Tao [4 ]
机构
[1] Fujian Med Univ, Dept Clin Lab, Quanzhou Hosp 1, 248 East St, Quanzhou 362002, Fujian, Peoples R China
[2] Hosp Nanan City, Dept Clin Lab, Nanan, Peoples R China
[3] Yongchun Hosp Tradit Chinese Med, Dept Clin Lab, Shanghai, Peoples R China
[4] Fujian Med Univ, Sch Basic Med Sci, Dept Immunol, 1 Xue Fu North Rd, Fuzhou 350122, Fujian, Peoples R China
关键词
liver cancer; matrix metalloproteinase‐ 9; prognosis; small ubiquitin‐ like modifier; like modifier 2; vascular endothelial growth factor; MESENCHYMAL TRANSITION; PROTEIN MODIFICATION; LIVER-CANCER; SUMOYLATION; STABILITY; DIAGNOSIS; METASTASIS; MODIFIERS; ANTIGEN;
D O I
10.1002/2211-5463.13173
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study aimed to evaluate the prognostic value and biological function of small ubiquitin-like modifier 2 (SUMO2) in hepatocellular carcinoma (HCC). SUMO2 expression in HCC tissues was markedly higher than that in normal liver tissues, and patients with high SUMO2 expression had significantly shorter median overall survival than those with low SUMO2 expression. Furthermore, SUMO2 expression was closely correlated with lymph node metastasis and vascular invasion and was a predictor of poor prognosis. The knockdown of SUMO2 in two HCC cell lines (SMMC-7721 and Bel-7404) dramatically suppressed their proliferation, migration and invasion. Western blot analysis showed that the downregulation of SUMO2 significantly reduced the expression of Ki-67, matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) in SMMC-7721 and Bel-7404 cells. Similarly, quantitative reverse transcription-PCR revealed consistently decreased expression of MMP-9 and VEGF. Our data suggest that SUMO2 promotes proliferation, migration and invasion of HCC cells via mechanisms involving MMP-9 and VEGF. Therefore, SUMO2 may be a prognostic factor and a promising therapeutic target for patients with HCC.
引用
收藏
页码:1771 / 1784
页数:14
相关论文
共 43 条
[1]   SUMOylation in carcinogenesis [J].
Bettermann, Kira ;
Benesch, Martin ;
Weis, Serge ;
Haybaeck, Johannes .
CANCER LETTERS, 2012, 316 (02) :113-125
[2]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[3]   Ubiquitin-like Protein Conjugation: Structures, Chemistry, and Mechanism [J].
Cappadocia, Laurent ;
Lima, Christopher D. .
CHEMICAL REVIEWS, 2018, 118 (03) :889-918
[4]   Post-translational modifiers of liver kinase B1/serine/threonine kinase 11 in hepatocellular carcinoma [J].
Cardoso Delgado, Teresa ;
Lopitz-Otsoa, Fernando ;
Luz Martinez-Chantar, Maria .
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2019, 6 :85-91
[5]   VEGF as a key mediator of angiogenesis in cancer [J].
Carmeliet, P .
ONCOLOGY, 2005, 69 :4-10
[6]   Narrower insight to SIRT1 role in cancer: A potential therapeutic target to control epithelial-mesenchymal transition in cancer cells [J].
Choupani, Jalal ;
Derakhshan, Sima Mansoori ;
Bayat, Sahar ;
Alivand, Mohammad Reza ;
Khaniani, Mahmoud Shekari .
JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (06) :4443-4457
[7]   The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia [J].
Di Costanzo, Antonella ;
Del Gaudio, Nunzio ;
Conte, Lidio ;
Dell'Aversana, Carmela ;
Vermeulen, Michiel ;
de The, Hugues ;
Migliaccio, Antimo ;
Nebbioso, Angela ;
Altucci, Lucia .
ONCOGENE, 2018, 37 (19) :2559-2572
[8]   Metastasis: recent discoveries and novel treatment strategies [J].
Eccles, Suzanne A. ;
Welch, Danny R. .
LANCET, 2007, 369 (9574) :1742-1757
[9]   Sumoylation: A Regulatory Protein Modification in Health and Disease [J].
Flotho, Annette ;
Melchior, Frauke .
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 82, 2013, 82 :357-385
[10]   Precision diagnosis and treatment of liver cancer in China [J].
Fu, Jing ;
Wang, Hongyang .
CANCER LETTERS, 2018, 412 :283-288